INAB

SEC source: 0001682638-26-000006 · form4-05292026_090552.xml · nonDerivative · entry 1

FAIRBAIRN EMILY · CIK 0001682638 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: Represents a bona fide gift for no consideration to a 501(c)(3) charitable foundation.

F2 · ownership.nature: The securities are held by Malcom and Emily Fairbairn 2010 CRUT (the "CRUT"). The Reporting Person is a trustee of the CRUT.

SEC source: 0001874384-26-000004 · form4-05122026_040517.xml · derivative · entry 1

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,250

Underlying: Common Stock · 56,250 shares

Expires 2036-05-09

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001898521-26-000004 · form4-05122026_040516.xml · derivative · entry 1

Rochlin Kate · CIK 0001898521 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-05-09

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001853815-26-000002 · form4-05122026_040512.xml · derivative · entry 1

Greenwood Luba · CIK 0001853815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2036-05-09

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001434099-26-000002 · form4-05122026_040506.xml · derivative · entry 1

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2036-05-09

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001682638-26-000004 · form4-05122026_040510.xml · derivative · entry 1

FAIRBAIRN EMILY · CIK 0001682638 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2036-05-09

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001830914-26-000004 · form4-05122026_040514.xml · derivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,500

Underlying: Common Stock · 154,500 shares

Expires 2036-05-09

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001830059-26-000004 · form4-05122026_040519.xml · derivative · entry 1

Lamb Lawrence · CIK 0001830059 · EVP and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,000

Underlying: Common Stock · 54,000 shares

Expires 2036-05-09

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001839156-26-000002 · form4-05122026_040508.xml · derivative · entry 1

Epperly Corinne · CIK 0001839156 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2036-05-09

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001975028-26-000002 · form4-05122026_040505.xml · derivative · entry 1

Graff Jeremy R. · CIK 0001975028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2036-05-09

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001874384-26-000002 · form4-02062026_040219.xml · derivative · entry 1

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2036-02-04

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001898521-26-000002 · form4-02062026_040217.xml · derivative · entry 1

Rochlin Kate · CIK 0001898521 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2036-02-04

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001830059-26-000002 · form4-02062026_040221.xml · derivative · entry 1

Lamb Lawrence · CIK 0001830059 · EVP and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,000

Underlying: Common Stock · 72,000 shares

Expires 2036-02-04

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001830914-26-000002 · form4-02062026_040216.xml · derivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,000

Underlying: Common Stock · 206,000 shares

Expires 2036-02-04

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on February 4, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001874384-25-000003 · form4-12232025_061208.xml · nonDerivative · entry 1

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,482

F1 · balance_after: Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.

SEC source: 0001898521-25-000003 · form4-12232025_061210.xml · nonDerivative · entry 1

Rochlin Kate · CIK 0001898521 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,085

F1 · balance_after: Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.

SEC source: 0001643070-25-000005 · form4-12232025_061205.xml · nonDerivative · entry 1

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,514

F1 · balance_after: Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.

SEC source: 0001434099-25-000004 · form4-12232025_061203.xml · nonDerivative · entry 1

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,181

F1 · balance_after: Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.

SEC source: 0001682638-25-000004 · form4-12232025_061201.xml · nonDerivative · entry 1

FAIRBAIRN EMILY · CIK 0001682638 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 724,637

F1 · ownership.nature: The securities are held by Malcom and Emily Fairbairn 2010 CRUT (the "CRUT"). The Reporting Person is a trustee of the CRUT.

SEC source: 0001830914-25-000003 · form4-12232025_061207.xml · nonDerivative · entry 1

Ho William Tai-Wei · CIK 0001830914 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,168

F1 · balance_after: Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.

SEC source: 0001415889-25-012654 · form4-05122025_040520.xml · derivative · entry 1

Greenwood Luba · CIK 0001853815 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,150

Underlying: Common Stock · 63,150 shares

Expires 2035-05-08

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-25-012649 · form4-05122025_040507.xml · derivative · entry 1

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,150

Underlying: Common Stock · 63,150 shares

Expires 2035-05-08

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-25-012650 · form4-05122025_040509.xml · derivative · entry 1

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,150

Underlying: Common Stock · 63,150 shares

Expires 2035-05-08

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-25-012652 · form4-05122025_040514.xml · derivative · entry 1

FAIRBAIRN EMILY · CIK 0001682638 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,150

Underlying: Common Stock · 63,150 shares

Expires 2035-05-08

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-25-012651 · form4-05122025_040512.xml · derivative · entry 1

Epperly Corinne · CIK 0001839156 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,150

Underlying: Common Stock · 63,150 shares

Expires 2035-05-08

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001415889-25-012653 · form4-05122025_040518.xml · derivative · entry 1

Graff Jeremy R. · CIK 0001975028 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,150

Underlying: Common Stock · 63,150 shares

Expires 2035-05-08

F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001104659-25-045738 · tm2514380-1_4seq1.xml · derivative · entry 10

Kreis Leslie W. · CIK 0001813316 · 10% owner

BIOS Fund III, LP · CIK 0001791917 · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner

BP Directors, LP · CIK 0001813311 · 10% owner

Bios Equity Partners, LP · CIK 0001813314 · 10% owner

Cavu Management, LP · CIK 0001813270 · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 0

Underlying: Common Stock · 574,241 shares

Expires 2028-12-13

F1 · kind: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · price: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-25-045738 · tm2514380-1_4seq1.xml · derivative · entry 9

Kreis Leslie W. · CIK 0001813316 · 10% owner

BIOS Fund III, LP · CIK 0001791917 · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner

BP Directors, LP · CIK 0001813311 · 10% owner

Bios Equity Partners, LP · CIK 0001813314 · 10% owner

Cavu Management, LP · CIK 0001813270 · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 0

Underlying: Common Stock · 574,241 shares

Expires 2025-10-04

F1 · kind: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · price: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-25-045738 · tm2514380-1_4seq1.xml · derivative · entry 8

Kreis Leslie W. · CIK 0001813316 · 10% owner

BIOS Fund III, LP · CIK 0001791917 · 10% owner

BIOS Fund III QP, LP · CIK 0001791916 · 10% owner

BIOS Fund III NT, LP · CIK 0001791910 · 10% owner

Bios Equity Partners II, LP · CIK 0001813313 · 10% owner

BIOS Equity Partners III, LP · CIK 0001831976 · 10% owner

BP Directors, LP · CIK 0001813311 · 10% owner

Bios Equity Partners, LP · CIK 0001813314 · 10% owner

Cavu Management, LP · CIK 0001813270 · 10% owner

Cavu Advisors, LLC · CIK 0001813310 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 2,431,763

Underlying: Common Stock · 1,148,482 shares

Expires not disclosed

F1 · price: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · derivative.exercise_date: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · derivative.expiration_date: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-25-045741 · tm2514380-2_4seq1.xml · derivative · entry 10

Fletcher Aaron G.L. · CIK 0001789490 · 10% owner

BIOS Fund II, LP · CIK 0001714576 · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · 10% owner

Bios Clinical Opportunity Fund, LP · CIK 0001988639 · 10% owner

Bios Equity COF, LP · CIK 0002000747 · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 0

Underlying: Common Stock · 574,241 shares

Expires 2028-12-13

F1 · kind: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · price: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-25-045741 · tm2514380-2_4seq1.xml · derivative · entry 9

Fletcher Aaron G.L. · CIK 0001789490 · 10% owner

BIOS Fund II, LP · CIK 0001714576 · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · 10% owner

Bios Clinical Opportunity Fund, LP · CIK 0001988639 · 10% owner

Bios Equity COF, LP · CIK 0002000747 · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 0

Underlying: Common Stock · 574,241 shares

Expires 2025-10-04

F1 · kind: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · price: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001104659-25-045741 · tm2514380-2_4seq1.xml · derivative · entry 8

Fletcher Aaron G.L. · CIK 0001789490 · 10% owner

BIOS Fund II, LP · CIK 0001714576 · 10% owner

BIOS Fund II QP, LP · CIK 0001716869 · 10% owner

BIOS Fund II NT, LP · CIK 0001728851 · 10% owner

BIOS Incysus Co-Invest I, LP · CIK 0001740029 · 10% owner

Bios Clinical Opportunity Fund, LP · CIK 0001988639 · 10% owner

Bios Equity COF, LP · CIK 0002000747 · 10% owner

BIOS Capital Management, LP · CIK 0001813845 · 10% owner

BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bios Clinical Opportunity Fund, LP

Disclosed balance after: 2,431,763

Underlying: Common Stock · 1,148,482 shares

Expires not disclosed

F1 · price: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · derivative.exercise_date: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F1 · derivative.expiration_date: Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.

F5 · ownership.nature: Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. Bios Management is the general partner of Bios Equity COF. Bios Advisors is the general partner of Bios Management. Bios Management and are entities managed and controlled by Mr. Fletcher. Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios COF. Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and Bios Equity COF, Mr. Fletcher, Bios Management and Bios Advisors may be deemed to beneficially own the securities held directly by Bios COF.

F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0001415889-25-012290 · form4-05072025_080509.xml · derivative · entry 4

Ho William Tai-Wei · CIK 0001830914 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,967

Underlying: Common Stock · 81,967 shares

Expires not disclosed

F4 · kind: Pursuant to an Exchange Letter Agreement, dated April 26, 2025 (the "Exchange Agreement"), by and between the Company and the Reporting Person, the Reporting Person surrendered to the Company for cancellation the Series A Warrants for a like number of Pre-Funded Warrants to purchase common stock, with a per share exercise price of $0.0001 per share.

F2 · derivative.exercise_date: Fully vested and exercisable.

F6 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. The Pre-Funded Warrants are subject to certain exercise limitations.

SEC source: 0001415889-25-012290 · form4-05072025_080509.xml · derivative · entry 3

Ho William Tai-Wei · CIK 0001830914 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 81,967 shares

Expires 2025-10-04

F4 · kind: Pursuant to an Exchange Letter Agreement, dated April 26, 2025 (the "Exchange Agreement"), by and between the Company and the Reporting Person, the Reporting Person surrendered to the Company for cancellation the Series A Warrants for a like number of Pre-Funded Warrants to purchase common stock, with a per share exercise price of $0.0001 per share.

F5 · price: The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-25-012288 · form4-05072025_080505.xml · derivative · entry 4

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2025-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-25-012288 · form4-05072025_080505.xml · nonDerivative · entry 1

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,071

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-012289 · form4-05072025_080507.xml · derivative · entry 4

Rochlin Kate · CIK 0001898521 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,295 shares

Expires 2025-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-25-012289 · form4-05072025_080507.xml · nonDerivative · entry 1

Rochlin Kate · CIK 0001898521 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,169

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-012287 · form4-05072025_080503.xml · derivative · entry 8

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,000 shares

Expires 2025-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-25-012287 · form4-05072025_080503.xml · derivative · entry 5

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 102,459 shares

Expires 2025-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-25-012287 · form4-05072025_080503.xml · nonDerivative · entry 2

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-012287 · form4-05072025_080503.xml · nonDerivative · entry 1

Roemer Alan S. · CIK 0001643070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 387,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-012286 · form4-05072025_080501.xml · derivative · entry 9

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 81,967 shares

Expires 2025-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-25-012286 · form4-05072025_080501.xml · derivative · entry 6

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 81,967 shares

Expires 2025-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-25-012286 · form4-05072025_080501.xml · nonDerivative · entry 2

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 681,538

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-012286 · form4-05072025_080501.xml · nonDerivative · entry 1

Brandt Peter C. · CIK 0001434099 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 599,571

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-012288 · form4-05072025_080505.xml · derivative · entry 6

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,492

Underlying: Common Stock · 20,492 shares

Expires 2028-12-13

F4 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.

F4 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-25-012288 · form4-05072025_080505.xml · derivative · entry 5

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,492 shares

Expires 2028-12-13

F4 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.

F3 · price: The reported securities are included within 20,492 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock.

F4 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-25-012288 · form4-05072025_080505.xml · derivative · entry 3

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2025-05-02

F1 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged.

F1 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged.

F2 · derivative.exercise_date: Fully vested and exercisable.

SEC source: 0001415889-25-012288 · form4-05072025_080505.xml · derivative · entry 2

McCall Patrick · CIK 0001874384 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,492

Underlying: Common Stock · 15,000 shares

Expires 2025-10-04

F1 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged.

F1 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged.

F3 · price: The reported securities are included within 20,492 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock.

F2 · derivative.exercise_date: Fully vested and exercisable.